Multiple sclerosis (MS) as a complex neurological disease can be due to vitamin D deficiency. CYP27B1 is referred to as a vitamin D metabolizing enzyme.
MATERIALS AND METHODS:
This study compared the expression level of CYP27B1 in Relapsing-Remitting MS (RRMS) patients with normal individuals in Iran. The RNA was extracted from 50 RRMS patients and 50 normal controls. Quantitative RT-PCR was adopted to measure the expression level of CYP27B1 gene.
RESULTS:
The expression level of CYP27B1gene was significantly lower in the RRMS patients than their normal counterparts (P value = 0.04). Also, the RRMS females participating had a significant reduction in CYP27B1 gene expression compared to normal females (P-Value = 0.01). In addition, the correlation between CYP27B1 expression level, and the risk of Expanded Disability Status Scale of Kurtzke (EDSS) was not linear. Additionally, there was no significant correlation between expression status of CYP27B1gene and duration of the disease.
CONCLUSION:
A significant decrease in the expression level of CYP27A1 in female patients could indicate their greater vulnerability to MS than the male patients.
ConfavreuxC. and VukusicS., Natural history of multiple sclerosis: A unifying concept, Brain129(3) (2006), 606-616.
2.
ColesA.J., CompstonD., SelmajK.W., LakeS.L., MoranS., MargolinD.H. et al., Alemtuzumab vs. interferon beta-1a in early multiple sclerosis, N Engl J Med.359(17) (2008), 1786-1801.
3.
SahraianM.A., PakdamanH. and HarandiA.A., Is it time to revise the classification of geographical distribution of multiple sclerosis? Iranian Journal of Neurology11(2) (2012), 77-78.
4.
EftekharianM.M., GhannadM.S., TaheriM., RoshanaeiG., MazdehM., MusaviM. and HormozM.B., Frequency of viral infections and environmental factors in multiple sclerosis, Human Antibodies (2015) (Preprint), 1-7.
5.
Pierrot-DeseillignyC. and SouberbielleJ.-C., Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis? Brain133(7) (2010), 1869-1888.
6.
MazdehM., SeifiradS., KazemiN., SeifrabieM.A., DehghanA. and AbbasiH., Comparison of vitamin D3 serum levels in new diagnosed patients with multiple sclerosis versus their healthy relatives, Acta Medica Iranica51(5) (2013), 289.
7.
BhallaA.K., AmentoE., SerogB. and GlimcherL., 1, 25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation, The Journal of Immunology133(4) (1984), 1748-1754.
8.
SundqvistE., BäärnhielmM., AlfredssonL., HillertJ., OlssonT. and KockumI., Confirmation of association between multiple sclerosis and CYP27B1, European Journal of Human Genetics18(12) (2010), 1349-1352.
9.
KimM.-S., FujikiR., KitagawaH. and KatoS., 1α , 25 (OH) 2 D 3-induced DNA methylation suppresses the human CYP27B1 gene, Molecular and Cellular Endocrinology265 (2007), 168-173.
10.
GrayR.W., OmdahlJ.L., GhazarianJ.G. and DeLucaH.F., 25-hydroxycholecalciferol-1-hydroxylase subcellular location and properties, Journal of Biological Chemistry247(23) (1972), 7528-7532.
11.
TakeyamaK.-I., KitanakaS., SatoT., KoboriM., YanagisawaJ. and KatoS., 25-Hydroxyvitamin D3 1α -hydroxylase and vitamin D synthesis, Science277(5333) (1997), 1827-1830.
12.
MonkawaT., YoshidaT., WakinoS., ShinkiT., AnazawaH., DelucaH.F. et al., Molecular cloning of cDNA and genomic DNA for human 25-hydroxyvitamin D 3 1α -hydroxylase, Biochemical and Biophysical Research Communications239(2) (1997), 527-533.
13.
McDonaldW.I., CompstonA., EdanG., GoodkinD., HartungH.P., LublinF.D. et al., Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis, Annals of Neurology50(1) (2001), 121-127.
14.
PolmanC.H., ReingoldS.C., EdanG., FilippiM., HartungH.P., KapposL. et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the ``McDonald Criteria'', Annals of Neurology58(6) (2005), 840-846.
15.
MazdehM., TaheriM., SayadA., BahramS., OmraniM.D., MovafaghA., InokoH., AkbariM.T., NorooziR., HajilooiM. and SolgiG., HLA genes as modifiers of response to IFN-β -1a therapy in relapsing-remitting multiple sclerosis, Pharmacogenomics17(5) (2016), 489-498.
16.
SayadA., The association of -330 interleukin-2 gene polymorphism and HLA-DR15 allele in Iranian patients with multiple sclerosis, Int J Immunogenet41(4) (2014), 330-334.
17.
SayadA., AllamehA., SayadA., NorouziniaM., AkbariM.T., SarzaeemA., AkbariA. and HajiH.R., The association of -475 and -631 interleukin-2 gene polymorphism with multiple sclerosis in Iranian patients, Cell Journal15(2) (2013), 124-129.
18.
SayadA., AllamehA., SayadA., NorouziniaM. and SarzaeemA., The influence of -330 IL-2 gene polymorphism on relapsing remitting and secondary progressive course multiple sclerosis in Iranian patients, Neurology of Asia Neurology Asia18(1) (2013), 83-86.
19.
TaheriM., NematiS.H., MovafaghA., EftekharianM.M., MirfakhraieR., SaberiM., MazdehM., SayadA., TRAIL gene expression analysis in multiple sclerosis patients, Human Antibodies1(1) 2016, 1-6.
20.
Yazdandoost HamedaniS.H., TaheriM., SajjadiE., OmraniM.D., Arsang-JangS.H., MazdehM., Tabatabaei PanahA.S., SayadA., Up regulation of MMP9 gene expression in female patients with multiple sclerosis, Human Antibodies1(1) (2016), 1-6.
21.
SadeghiH., TaheriM., MovafaghA., SajadiE., Arsang JangS.H., SayadA., VDR and CYP24A1 genes expression analysis in Iranian relapsing remitting Multiple sclerosis patients, Cell Journal19(3) (2017), in press.
22.
Pierrot-DeseillignyC. and SouberbielleJ.-C., Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis, Therapeutic Advances in Neurological Disorders (2013), 1756285612473513.
23.
RamagopalanS.V., DymentD.A., CaderM.Z., MorrisonK.M., DisantoG., MorahanJ.M. et al., Rare variants in the CYP27B1 gene are associated with multiple sclerosis, Annals of Neurology70(6) (2011), 881-886.
24.
BanM., CaillierS., MeroI.L., MyhrK.M., CeliusE.G., AarsethJ. et al., No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis, Annals of Neurology73(3) (2013), 430-432.
25.
SmoldersJ., ThewissenM., TheunissenR., PeelenE., KnippenbergS., MenheereP. et al., Vitamin D-related gene expression profiles in immune cells of patients with relapsing remitting multiple sclerosis, Journal of Neuroimmunology235(1) (2011), 91-97.
26.
SmoldersJ., SchuurmanK.G., van StrienM.E., MeliefJ., HendrickxD., HolE.M. et al., Expression of Vitamin D Receptor and Metabolizing Enzymes in Multiple Sclerosis - Affected Brain Tissue, Journal of Neuropathology & Experimental Neurology72(2) (2013), 91-105.
27.
SellnerJ., KrausJ., AwadA., MiloR., HemmerB. and StüveO., The increasing incidence and prevalence of female multiple sclerosis - a critical analysis of potential environmental factors, Autoimmunity Reviews10(8) (2011), 495-502.
